Setup

On March 17, 2026, Kim Rivers — founder, CEO, and 10% holder of Trulieve Cannabis (TCNNF) — acquired 2.5M shares open-market for $20.7M at $8.29. Six senior officers separately acquired shares the same day on December 1, 2025. The Q1 2026 earnings call on May 7 reported the first GAAP profitable quarter in company history. Two dated, independent idio catalysts converge in the next six months.

What the filing says

Q1 2026: revenue $287M, Adj EBITDA $100M (35% margin), OCF $56M, cash $353M, debt $290M — net cash positive $63M. GAAP net income $2M ($0.01 EPS) versus consensus -$0.05, a 300% surprise. FY2026 guidance: OCF ≥$250M, capex ≤$85M — ≈$165M FCF on a $1.6B market cap.

Uncertain tax position liability is $696M, the largest in the Big-5 MSO cohort. Rivers in Q&A: "we look at this as a when, not an if at this point, with very clear brackets around previous years and previous years exposure." She also named uplisting to a major US exchange as an active board initiative — the first explicit commitment. Texas TCUP conditional license groundbreak has started. The DEA manufacturing portal for Georgia pharmacy distribution opened on May 6 (the day before the call) with 140 pharmacies pre-registered.

What the market thinks

TCNNF is OTC — no liquid options market. The single covering analyst's $21 target is stale (May 2024, pre-rescheduling). TCNNF is up 92.8% on the year; cohort comp CURLF is up 370%. The current price implies neither the UTP balance-sheet path nor a Florida ballot pass: the $696M UTP is modeled under the slow IRS Appeals frame, and Florida is anchored to the 2024 fail at 56.7%.

Why the gap exists

CURLF released $92.3M of UTP in Q1 2026 via ASC 740 "more likely than not" reassessment tied to medical rescheduling. The release was auditor-mediated — it did not require an IRS Revenue Ruling or Treasury retroactivity guidance. The path is mechanically distinct from the Treasury/Appeals frame analysts model. TCNNF holds $696M UTP; if its auditor follows the CURLF playbook in the August or November 10-Q, $300-500M release is plausible — a 12-25% non-cash equity credit that removes the uplisting overhang.

The second gap is Florida anchor-bias. Amendment 3 in 2024 failed at 56.7% versus the 60% supermajority. Smart & Safe Florida refiled January 14, 2025 for November 2026. The Q1 call disclosed no 2026 campaign budget — analysts did not press. Florida Amendment 2 (medical) provides the second-try precedent: 57.6% fail in 2014 to 71.3% pass in 2016.

A FL ballot fail does not affect the audit firm's MLTN reassessment, and an ASC 740 release does not affect FL voting.

Risks (ranked)

1. FL ballot fails the 60% supermajority again. 2024 fell 3.3 points short. If polling tracks below 55% in October, the binary truncates and TCNNF re-rates 20-35% lower.
2. TCNNF auditor declines the CURLF playbook. Trulieve's prior-year posture ("280E doesn't apply AT ALL") is more aggressive than CURLF's narrower COGS argument. Q1 2026 produced no release despite the same regulatory facts — the auditor is more conservative or waiting on IRS Appeals progress. If Q2 hardens the tax footnote MLTN language, the ASC 740 path closes.
3. Cohort late-cycle. CURLF +370%, sector +200%+ on the year. Re-rating partially absorbed.
4. No options market. Cannot hedge with derivatives; only cohort short available.

Catalysts

• August 6, 2026 — Q2 2026 10-Q. ASC 740 trigger #1. Hard signal: UTP movement line. Soft signal: tax footnote MLTN language vs Q4 2025.
• September-October 2026 — FL ballot polling cycle; Smart & Safe Florida quarterly campaign finance filings.
• November 3, 2026 — Florida adult-use ballot vote. Binary, primary catalyst.
• November 2026 — Q3 2026 10-Q. ASC 740 trigger #2.
• June 29 - July 15, 2026 — DEA adult-use rescheduling hearing. Sectoral.

What would change our mind

• Q2 10-Q tax footnote MLTN language hardens (e.g., shifts toward "less likely than not") → ASC 740 path closes.
• Treasury issues prospective-only ruling explicitly excluding retroactive UTP.
• Smart & Safe Florida internal polling leaks below 55% YES, or TCNNF Q2 campaign spending disclosure comes in below $30M for 2026.
• Audit firm change announcement at TCNNF.
• TCNNF breaks $7 on volume (50-day MA $7.05, 200-day MA $7.21).

LR signal: 1.5

Two independent dated catalysts within six months, primary-source insider confirmation at current spot, cohort precedent established for the asymmetric path, named invalidation criteria. Market frame demonstrably skips the ASC 740 mechanism. Memo LR in the 1.2-1.8 bullish range. Not >2.0: cannabis catalysts have run off the rails before, and the FL binary risk is real and not mitigable within the position.

Evidence